LONDON, June 30, 2014 /PRNewswire/ --
On Friday, June 27, 2014, the NASDAQ Composite ended at 4,397.93, up 0.43%, the Dow Jones Industrial Average edged 0.03% higher to finish the day at 16,851.84, and the S&P 500 closed at 1,960.96, up 0.19%. The gains were broad based with seven out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.06, down 0.21%, whereas the index has advanced 4.44% in the previous three months. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Thoratec Corp. (NASDAQ: THOR), Unilife Corp. (NASDAQ: UNIS) and VIVUS Inc. (NASDAQ: VVUS). Free technical research on KERX, THOR, UNIS and VVUS can be downloaded upon signing up at:
http://www.investor-edge.com/4332-register
Shares in Keryx Biopharmaceuticals Inc. edged 0.19% higher to close the day at $15.51. The stock recorded a trading volume of 1.96 million shares, below its three months average volume of 2.20 million shares. The company shares oscillated between $15.37 and $15.80 during the session. Over the last three trading sessions and over the past one month, Keryx Biopharmaceuticals Inc.'s shares have advanced 3.13% and 17.86%, respectively. Further, the stock has gained an upside 19.77% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages of $13.87 and $13.44, respectively. Additionally, shares of Keryx Biopharmaceuticals Inc. have a Relative Strength Index (RSI) of 73.14. Sign up today to read free research on KERX at:
http://www.investor-edge.com/4332-KERX-30Jun2014.pdf
On Friday, Thoratec Corp.'s stock recorded a trading volume of 0.62 million shares, higher than its three months average volume of 0.55 million shares. The stock ended the day at $34.93, which was 1.39% above its previous day's closing of $34.45, and registered an intraday range of $34.23 and $34.98. Shares of the company traded at a PE ratio of 25.44. Although Thoratec Corp.'s stock has lost 4.56% on YTD basis, it has advanced 2.13% in the previous three trading sessions and 5.43% in the last one month. The stock is trading above its 50-day moving average of $33.06, while the 50-day moving average is below its 200-day moving average of $36.23. Furthermore, Thoratec Corp.'s stock has an RSI of 64.46. Sign up today to read free research on THOR at:
http://www.investor-edge.com/4332-THOR-30Jun2014.pdf
Unilife Corp.'s stock finished the Friday's session 1.06% higher at $2.87. A total of 1.30 million shares were traded, which was above its three months average volume of 1.02 million shares. The stock vacillated between $2.78 and $2.89 during the session. Over the last one month and over the previous three months, Unilife Corp.'s shares have fallen by 3.69% and 27.89%, respectively. Additionally, from the beginning of 2014, the company's stock has lost 34.77%. The stock is trading below its 50-day and 200-day moving averages of $3.02 and $3.74, respectively. Moreover, Unilife Corp.'s stock has an RSI of 44.58. Sign up today to read free research on UNIS at:
http://www.investor-edge.com/4332-UNIS-30Jun2014.pdf
On Friday, VIVUS Inc.'s stock fluctuated between $5.03 and $5.22 before ending the session 2.96% higher at $5.22. The stock reported a trading volume of 2.51 million shares, below its three months average volume of 2.90 million shares. VIVUS Inc.'s shares have advanced 1.75% in the previous three trading sessions and 1.95% in the last one month, while the stock has lost 42.51% on YTD basis. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $7.50 is greater than its 50-day moving average of $5.10. Shares of VIVUS Inc. have an RSI of 52.65. Sign up today to read free research on VVUS at:
http://www.investor-edge.com/4332-VVUS-30Jun2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
